Low-dose combined oral contraceptive use is associated with lower bone mineral content variation in adolescents over a 1-year period

Autor(es)

Biason, Talita Poli ^[1] ; Lederer Goldberg, Tamara Beres ^[1] ; Kurokawa, Cilmery Suemi ^[2] ; Moretto, Maria Regina ^[2] ; Teixeira, Altamir Santos ^[3] ; de Carvalho Nunes, Helio Rubens ^[4]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ, Botucatu Sch Med, Grad Program Gynecol Obstet & Mastol, Dept Pediat, Adolescent Med Discipline, UNESP, Sao Paulo - Brazil

^[2] Sao Paulo State Univ, Botucatu Sch Med, Clin & Expt Pediat Res Ctr, Dept Pediat, UNESP, Sao Paulo - Brazil

^[3] Sao Paulo State Univ, Botucatu Sch Med, Dept Trop Dis & Diagnost Imaging, UNESP, Sao Paulo - Brazil

^[4] Sao Paulo State Univ, Botucatu Sch Med, UNESP, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: BMC Endocrine Disorders; v. 15, APR 3 2015.
• Citações Web of Science: 9

Resumo

Background: Low-dose combined oral contraceptives (COCs) can interfere with bone mass acquisition during adolescence. This study aimed to evaluate bone mineral density (BMD) and bone mineral content (BMC) in female adolescents taking a standard low-dose COC (ethinylestradiol 20 mu g/desogestrel 150 mu g)over a 1-year period and to compare their data with those of healthy adolescents from the same age group not taking COCs. Methods: This was a non-randomized parallel-control study with a 1-year follow-up. Sixty-seven adolescents aged from 12 to 19 years, divided into COC users (n = 41) taking 20 mu g ethinylestradiol/150 mu g desogestrel and COC non-user controls (n = 26), were evaluated by bone densitometry examinations at baseline and after 12 months. Comparisons between the groups at the study onset were performed using the Mann-Whitney test with the significance level fixed at 5% or p < 0.05. Comparisons between the groups at the study onset and after 12 months were based on variations in the median percentages for bone mass variables. Results: The COC users presented with low bone mass acquisition in the lumbar spine, and had BMD and BMC median variations of 2.07% and +1.57%, respectively, between the measurements at baseline and 12 months. The control group had median variations of +12.16% and +16.84% for BMD and BMC, respectively, over the same period. The total body BMD and BMC showed similar evolutions during the study in both groups. Statistical significance (p < 0.05) was seen for the BMC percentage variation between COC users and non-users. Conclusions: Use of a low-dose COC (ethinylestradiol 20 mu g/desogestrel 150 mu g) was associated with lower bone mass acquisition in adolescents during the study period. (AU)

• Processo FAPESP: 11/05991-0 - O impacto do excesso de gordura corporal sobre a densidade mineral óssea e a remodelação óssea: estudo com adolescentes sobrepesos, obesos e superobesos (corrigido)
• Beneficiário: Tamara Beres Lederer Goldberg
• Modalidade de apoio: Auxílio à Pesquisa - Regular